Diabetic Retinopathy Market to Reach USD 15.1 Billion by 2032

According to analysts at Vantage Market Research, the Global Diabetic Retinopathy Market size is worth USD 9.1 Billion in 2023 and is projected to reach USD 15.1 Billion by 2032, growing at a CAGR (Compound Annual Growth Rate) of 6.5% from 2024 to 2032. Key trends include advanced diagnostics, anti-VEGF therapies, telemedicine growth and biosimilar adoption.

Market Overview

Diabetic retinopathy is caused by the higher level of sugar in the blood which leads to the blockage of microscopic blood vessels that provide blood to the retinas, due to the blockage cuts off the blood supply. Due to these, the eye attempts to create a new blood vessel, but these types of blood vessels may not form properly and lead to leakage, which might cause spots or dark strings floating on the vision, blurred vision, fluctuating vision, and sometimes vision loss. The increasing risk of diabetic retinopathy in the senior population due to the greater level of diabetes drives the increasing demand in the diabetic retinopathy market.

The increasing investments by the leading key players in the development of technologies in ophthalmic devices promises a beneficial opportunity for the market. Technological advancement such as emergence of artificial intelligence in diabetic retinopathy devices for efficiency in the treatment drives the growth of the market. Further technological acceptance such as optical coherence tomography used in the diagnosis allows the provision of cross-sectional images with superior quality that allows doctors to make better decisions. Thus, all these advancements in diabetic retinopathy devices are driving the growth of the market.

EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review

• In June 2022, Regeneron Pharmaceuticals Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for review the EYLEA® (aflibercept) Injection supplemental Biologics License Application (sBLA) for an every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR). The target action date for the FDA decision is February 28, 2023

Key Takeaways from the Report

• In 2024, North America dominated the market with 39.40% market share. Market is driven by the rising prevalence of neurological disorders and increased insurance coverage
• Based on the Type, the Non-Proliferative Diabetic Retinopathy (NPDR) category accounted for significant market share of 71.40%. The primary causes of the high incidence are the aging population and the increase in diabetes-related blindness
• Based on the Management, the Anti-VEGF category accounted for significant market share of 91.30%. The segment drives the growth by efficiency and efficacy of these drugs in the treatment of diabetic retinopathy.
• In 2024, by Distribution Channel, Hospitals and Pharmacies dominated the market with significant market share. The growth of the segment is attributed to the increasing prevalence of surgical procedures in the hospitals

Top Companies

• Bayer AG
• ABBVIE Inc
• Novartis AG
• Alimera Sciences
• Genentec Inc
• Ampio Pharmaceuticals Inc
• Kowa Company Ltd
• BCNPeptides
• Oxurion NV
• Sirnaomics

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

New FDA Clearance Makes Eyenuk the First Company with Multiple Cameras for Autonomous AI Detection of Diabetic Retinopathy

• In June 2023, Eyenuk, a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, has received U.S. Food and Drug Administration (FDA) clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras